Yue Shentu

Merck & Co., Inc., Rahway, NJ, USA (United States)

MedicineMathematicsEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer”.

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

New England Journal of Medicine(2016)10.1056/nejmoa1606774

N/A

1.4DataRank · unranked

9979 citations

Delvys Rodríguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp +16 more

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

The Lancet(2016)10.1016/s0140-6736(15)01281-7

N/A

1.3DataRank · unranked

6497 citations

Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han +20 more